Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeXT Personal®, Personalis’ ultra-sensitive, whole genome-based liquid biopsy assay for detection of minimal residual disease (MRD) and recurrence in cancer. Members of Tempus’ commercial team can now engage in discussions with doctors about the use of the NeXT Personal Dx test for breast and lung cancers, and for immunotherapy monitoring across all solid tumors.

“Today’s announcement opens up new possibilities for cancer patients and we’re excited to be working with Tempus to reach oncologists through our collective efforts,” said Chris Hall, CEO, Personalis.

This announcement follows the launch of NeXT Personal Dx in early access last October. NeXT Personal Dx helps oncologists detect cancer recurrence earlier and aids in treatment decision-making, with the ability to detect in blood just one DNA fragment from cancer in the midst of 1 million non-cancerous DNA fragments. The ultra-sensitive, personalized MRD assay identifies up to 1,800 somatic variants unique to each patient’s tumor, supporting physicians in making informed, individualized management decisions for patients. Personalis collaborators are also presenting new data on NeXT Personal at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in breast cancer and immunotherapy monitoring, including two oral presentations.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest time points, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to potential testing volume, the attributes, advantages or clinical validity of the NeXT Personal Dx test, or the expected benefits of Personalis’ collaboration with Tempus. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis’ ability to demonstrate attributes, advantages or clinical validity of the NeXT Personal Dx test, the success of Tempus’ sales and marketing efforts, and the adoption and use of the NeXT Personal Dx test by oncologists. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (SEC) on February 28, 2024, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.